BCYC

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.93
Percentage change -6.42	%

Peers: EXEL FATE KPTI ARGX IMTX MRNA AGEN ADAP AFMD IOVA

| Held by: IBB MSSM GWX ONEQ MEDX MEDI CNCR BBC QQQS BIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.30	Insider Own	4.99%	Shs Outstand	69.02M	Perf Week	-3.91%
Market Cap	939.81M	Forward P/E	-	EPS next Y	-3.52	Insider Trans	71.35%	Shs Float	65.57M	Perf Month	-1.40%
Income	-167.25M	PEG	-	EPS next Q	-0.86	Inst Own	62.74%	Short Float	6.01%	Perf Quarter	-49.74%
Sales	36.97M	P/S	25.42	EPS this Y	40.58%	Inst Trans	1.73%	Short Ratio	6.62	Perf Half Y	-41.74%
Book/sh	12.04	P/B	1.13	EPS next Y	-16.69%	ROA	-20.45%	Short Interest	3.94M	Perf Year	-25.02%
Cash/sh	12.91	P/C	1.05	EPS next 5Y	-	ROE	-26.82%	52W Range	12.17 - 28.67	Perf YTD	-2.74%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.36%	ROI	-19.99%	52W High	-52.51%	Beta	0.93
Dividend TTM	-	Quick Ratio	17.13	Sales past 5Y	24.55%	Gross Margin	80.63%	52W Low	11.89%	ATR (14)	1.14
Dividend Ex-Date	-	Current Ratio	17.13	EPS Y/Y TTM	33.96%	Oper. Margin	-635.58%	RSI (14)	36.09	Volatility	7.48% 8.48%
Employees	284	Debt/Eq	0.01	Sales Y/Y TTM	48.46%	Profit Margin	-452.39%	Recom	1.47	Target Price	32.15
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	40.65%	Payout	-	Rel Volume	0.29	Prev Close	14.55
Sales Surprise	-60.76%	EPS Surprise	7.11%	Sales Q/Q	-49.19%	Earnings	Oct 31 BMO	Avg Volume	595.28K	Price	13.62
SMA20	-6.59%	SMA50	-26.05%	SMA200	-37.99%	Trades		Volume	82,797	Change	-6.42%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-08-24	Initiated	Stephens	Equal-Weight	$25
Sep-06-24	Initiated	RBC Capital Mkts	Outperform	$35
Aug-07-24	Downgrade	B. Riley Securities	Buy → Neutral	$33 → $28
Sep-11-23	Upgrade	B. Riley Securities	Neutral → Buy
Aug-31-22	Initiated	Cowen	Outperform
Jul-28-22	Initiated	Barclays	Overweight	$30
Jul-06-22	Resumed	Canaccord Genuity	Buy	$60
Apr-13-22	Downgrade	B. Riley Securities	Buy → Neutral	$62 → $33
Apr-07-22	Resumed	Cantor Fitzgerald	Overweight	$100 → $80
Feb-14-22	Initiated	Morgan Stanley	Equal-Weight	$60
Dec-17-21	Initiated	SVB Leerink	Outperform	$70
Dec-09-21	Initiated	Needham	Buy	$85
Sep-30-21	Initiated	B. Riley Securities	Buy	$56
Apr-20-21	Initiated	JMP Securities	Mkt Outperform	$53
Oct-12-20	Initiated	Cantor Fitzgerald	Overweight	$30
Jun-12-20	Initiated	Oppenheimer	Outperform
Apr-17-20	Initiated	H.C. Wainwright	Buy	$25
Nov-14-19	Initiated	ROTH Capital	Buy	$17
Sep-11-19	Upgrade	Goldman	Neutral → Buy	$14
Jun-17-19	Initiated	Piper Jaffray	Overweight	$20

Show Previous Ratings

Jan-13-25 07:00AM	Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones (Business Wire) +13.90%
Jan-09-25 07:00AM	Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-03-25 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-20-24 03:27PM	First Solar, Frontier Communications, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-13-24 07:50AM	Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients (Benzinga) -31.33%
06:30PM	Loading…
Dec-12-24 06:30PM	Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification (Business Wire)
Dec-10-24 07:00AM	Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts (Business Wire)
Dec-02-24 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-25-24 05:30PM	Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update (Business Wire)
Nov-13-24 10:39AM	Is Bicycle Therapeutics plc (BCYC) Top Performing European Stock Heading into 2025? (Insider Monkey)
Nov-12-24 07:00AM	Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference (Business Wire)
Nov-01-24 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-31-24 07:00AM	Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results (Business Wire)
Oct-23-24 07:00AM	Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals (Business Wire)
Oct-17-24 02:29PM	Bicycle Therapeutics (BCYC): High-Growth UK Stock with Innovative Peptide Technology (Insider Monkey)
07:00AM	Loading…
Oct-16-24 07:00AM	Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress (Business Wire)
Oct-14-24 05:36AM	Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? (Zacks)
Oct-02-24 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-14-24 03:00AM	Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024 (Business Wire)
Sep-06-24 01:37PM	Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone (Benzinga)
Sep-03-24 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-21-24 07:00AM	Bicycle Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Aug-09-24 12:00PM	What Makes Bicycle Therapeutics (BCYC) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts See an 88.94% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High? (Zacks)
Aug-06-24 01:53PM	BCYC Stock Earnings: Bicycle Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +7.35%
07:05AM	Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results (Business Wire)
Aug-01-24 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-22-24 07:00AM	Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024 (Business Wire) +6.94%
Jun-27-24 09:40AM	Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year? (Zacks)
Jun-11-24 09:40AM	Is Bicycle Therapeutics (BCYC) Stock Outpacing Its Medical Peers This Year? (Zacks)
07:00AM	Loading…
Jun-03-24 07:00AM	Bicycle Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
May-24-24 12:25PM	Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M (Zacks)
09:55AM	Wall Street Analysts Think Bicycle Therapeutics (BCYC) Could Surge 85.52%: Read This Before Placing a Bet (Zacks)
May-23-24 05:05PM	Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting (Business Wire) +9.62%
07:00AM	Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing (Business Wire)
May-21-24 09:40AM	Is Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year? (Zacks)
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia)
May-06-24 12:00PM	Bicycle Therapeutics (BCYC) Moves to Buy: Rationale Behind the Upgrade (Zacks) -5.21%
09:55AM	Wall Street Analysts See a 77.22% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High? (Zacks)
May-02-24 01:54PM	BCYC Stock Earnings: Bicycle Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:44AM	Bicycle Therapeutics PLC (BCYC) Q1 2024 Earnings: Narrowing Losses Amidst Robust R&D Progress (GuruFocus.com)
07:00AM	Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results (Business Wire)
Apr-24-24 10:05AM	Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting (Business Wire)
Apr-02-24 07:00AM	Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-05-24 04:35PM	Bicycle Therapeutics to Present at the AACR Annual Meeting 2024 (Business Wire)
Feb-28-24 07:00AM	Bicycle Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Feb-20-24 07:05AM	Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-07-24 07:00AM	Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-22-24 10:54AM	15 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-05-24 02:02AM	Bicycle Therapeutics PLC CEO Kevin Lee Sells 8,703 Shares (GuruFocus.com)
Dec-14-23 07:00AM	Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day (Business Wire) -8.93%
Nov-30-23 07:00AM	Bicycle Therapeutics to Host R&D Day on December 14 (Business Wire) +6.51%
Nov-02-23 08:46AM	Bicycle Therapeutics PLC (BCYC) Reports Q3 2023 Financial Results and Upcoming R&D Day (GuruFocus.com)
07:00AM	Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day (Business Wire)
06:04AM	The Stage Is Set for a Rally: Canaccord Sees up to 290% Upside for These 3 Stocks (TipRanks)
Oct-30-23 07:00AM	Bicycle Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Oct-19-23 07:00AM	Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer (Business Wire)
04:00AM	Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director (GlobeNewswire)
Sep-14-23 10:12AM	Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates (Zacks)
Sep-12-23 07:54AM	Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up (Zacks) -7.27%
06:36AM	Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains? (Zacks)
Sep-11-23 02:19PM	Why Shares of Bicycle Therapeutics Were Rising on Monday (Motley Fool) +8.97%
07:00AM	Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer (Business Wire)
Sep-05-23 07:00AM	Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-03-23 06:59AM	Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (Business Wire)
Jul-18-23 07:00AM	Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire)
06:45AM	Investors in Bicycle Therapeutics (NASDAQ:BCYC) have seen favorable returns of 39% over the past three years (Simply Wall St.)
Jul-14-23 06:47AM	Bicycle Therapeutics PLC Sponsored ADR (BCYC) Soars 19.3%: Is Further Upside Left in the Stock? (Zacks)
Jul-13-23 06:40PM	Why Bicycle Therapeutics Stock Raced Ahead Today (Motley Fool) +19.32%
Jul-12-23 10:23PM	Bicycle Therapeutics Announces Pricing of $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares (Business Wire) -6.70%
04:01PM	Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares (Business Wire)
Jun-23-23 07:30AM	Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer (Business Wire) -6.05%
Jun-13-23 07:00AM	Bicycle Therapeutics to Participate in the TD Cowen Radiopharmaceutical Innovation Summit (Business Wire)
May-31-23 07:00AM	Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference (Business Wire)
May-14-23 08:05AM	Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook (Simply Wall St.)
May-11-23 06:59AM	Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023 (Business Wire)
May-10-23 08:00AM	Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology (Business Wire)
07:29AM	Bayer, Bicycle Therapeutics in cancer radiotherapy drug alliance (Reuters)
May-04-23 09:55AM	Wall Street Analysts Think Bicycle Therapeutics PLC Sponsored ADR (BCYC) Could Surge 146.31%: Read This Before Placing a Bet (Zacks)
07:00AM	Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (Business Wire)
06:45AM	Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets (Business Wire)
Apr-14-23 07:00AM	Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting (Business Wire) -7.11%
Apr-03-23 07:00AM	Bicycle Therapeutics Enhances Leadership Team with Key Appointments (Business Wire)
Mar-31-23 06:36AM	Broker Revenue Forecasts For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher (Simply Wall St.)
Mar-29-23 08:17AM	Bicycle (BCYC) up on Collaboration With Novartis for Conjugates (Zacks)
Mar-28-23 07:00AM	Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates (Business Wire) +11.06%
Feb-28-23 09:00AM	Bicycle Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
07:00AM	Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (Business Wire)
Feb-14-23 06:59AM	Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009 (Business Wire)
Feb-08-23 07:00AM	Bicycle Therapeutics to Participate in the SVB Securities Global Biopharma Conference (Business Wire)
Jan-29-23 09:46AM	Investors in Bicycle Therapeutics (NASDAQ:BCYC) have made a impressive return of 157% over the past three years (Simply Wall St.)
Jan-11-23 07:00AM	Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium (Business Wire)
Jan-04-23 07:00AM	Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (Business Wire)
Nov-10-22 09:09AM	Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting (Business Wire) +10.04%
Nov-09-22 08:03AM	Bicycle Therapeutics Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) +5.35%
Nov-08-22 07:00AM	Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update (Business Wire) +5.34%
05:03AM	What You Need To Know About The Bicycle Therapeutics plc (NASDAQ:BCYC) Analyst Downgrade Today (Simply Wall St.)
Nov-04-22 07:00AM	Bicycle Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Nov-03-22 07:00AM	Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (Business Wire)
Oct-10-22 07:00AM	Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program (Business Wire)

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	Jan 06 '25	Sale	15.00	2,686	40,290	32,146	Jan 06 07:30 PM
Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	Jan 02 '25	Sale	14.09	1,750	24,658	34,991	Jan 06 07:30 PM
Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	Jan 03 '25	Sale	14.75	159	2,345	34,832	Jan 06 07:30 PM
Young Alethia	Chief Financial Officer	Jan 02 '25	Sale	14.09	1,395	19,656	45,605	Jan 06 07:30 PM
Arroyo Santiago	CHIEF DEVELOPMENT OFFICER	Jan 02 '25	Sale	14.09	4,943	69,647	69,057	Jan 06 07:30 PM
Crockett Nigel	CHIEF BUSINESS OFFICER	Jan 02 '25	Sale	14.09	2,583	36,394	51,989	Jan 06 07:30 PM
Crockett Nigel	CHIEF BUSINESS OFFICER	Jan 03 '25	Sale	14.75	936	13,806	51,053	Jan 06 07:30 PM
Milnes Alistair	CHIEF OPERATING OFFICER	Jan 02 '25	Sale	14.09	4,578	64,504	100,724	Jan 06 07:30 PM
Milnes Alistair	CHIEF OPERATING OFFICER	Jan 03 '25	Sale	14.75	936	13,806	99,788	Jan 06 07:30 PM
Skynner Michael	CHIEF TECHNOLOGY OFFICER	Jan 02 '25	Sale	14.09	3,287	46,314	124,658	Jan 06 07:30 PM
Skynner Michael	CHIEF TECHNOLOGY OFFICER	Jan 03 '25	Sale	14.75	936	13,806	123,722	Jan 06 07:30 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Jan 02 '25	Sale	14.09	1,879	26,475	55,519	Jan 06 07:30 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Jan 03 '25	Sale	14.75	239	3,525	55,280	Jan 06 07:30 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Jan 02 '25	Sale	14.09	9,038	127,345	495,026	Jan 06 07:30 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Jan 03 '25	Sale	14.75	3,092	45,607	491,934	Jan 06 07:30 PM
Thompson Travis Alvin	Officer	Jan 06 '25	Proposed Sale	15.00	2,686	40,290		Jan 06 12:06 PM
Thompson Travis Alvin	Officer	Jan 02 '25	Proposed Sale	14.00	2,016	28,224		Jan 02 04:22 PM
Young Alethia	Officer	Jan 02 '25	Proposed Sale	14.00	1,395	19,530		Jan 02 04:21 PM
Arroyo Santiago	Officer	Jan 02 '25	Proposed Sale	14.00	4,943	69,202		Jan 02 04:20 PM
Hannay Michael Charles Ferguso	Officer	Jan 02 '25	Proposed Sale	14.00	2,145	30,030		Jan 02 04:18 PM
Crockett Nigel	Officer	Jan 02 '25	Proposed Sale	14.00	3,636	50,904		Jan 02 04:17 PM
Milnes Alistair	Officer	Jan 02 '25	Proposed Sale	14.00	5,631	78,834		Jan 02 04:16 PM
Skynner Michael	Officer	Jan 02 '25	Proposed Sale	14.00	4,340	60,760		Jan 02 04:15 PM
Lee Kevin	Officer	Jan 02 '25	Proposed Sale	14.00	12,516	175,224		Jan 02 04:14 PM
BAKER BROS. ADVISORS LP	Director	Dec 13 '24	Buy	13.76	985,397	13,559,485	9,537,643	Dec 17 06:03 PM
BAKER BROS. ADVISORS LP	Director	Dec 16 '24	Buy	15.34	500,000	7,670,900	9,995,274	Dec 17 06:03 PM
Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	Nov 11 '24	Option Exercise	5.67	2,575	14,608	24,234	Nov 13 07:43 PM
Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	Nov 11 '24	Sale	25.11	6,256	157,114	19,241	Nov 13 07:43 PM
Thompson Travis Alvin	Officer	Nov 11 '24	Proposed Sale	25.11	6,256	157,112		Nov 12 09:00 AM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Oct 03 '24	Sale	22.26	3,212	71,499	380,864	Oct 04 04:50 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Oct 03 '24	Sale	22.26	247	5,498	22,398	Oct 04 04:50 PM
Skynner Michael	CHIEF TECHNOLOGY OFFICER	Oct 03 '24	Sale	22.26	972	21,637	92,945	Oct 04 04:50 PM
Milnes Alistair	CHIEF OPERATING OFFICER	Oct 03 '24	Sale	22.26	972	21,637	70,302	Oct 04 04:50 PM
Crockett Nigel	CHIEF BUSINESS OFFICER	Oct 03 '24	Sale	22.26	972	21,637	45,822	Oct 04 04:50 PM
Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	Oct 03 '24	Sale	22.26	153	3,406	22,922	Oct 04 04:50 PM
Thompson Travis Alvin	Officer	Oct 03 '24	Proposed Sale	22.56	153	3,451		Oct 03 04:30 PM
Keen Nicholas	Officer	Oct 03 '24	Proposed Sale	22.56	308	6,948		Oct 03 04:28 PM
Hannay Michael Charles Ferguso	Officer	Oct 03 '24	Proposed Sale	22.56	247	5,572		Oct 03 04:25 PM
Crockett Nigel	Officer	Oct 03 '24	Proposed Sale	22.56	972	21,928		Oct 03 04:22 PM
Milnes Alistair	Officer	Oct 03 '24	Proposed Sale	22.56	972	21,928		Oct 03 04:19 PM
Skynner Michael	Officer	Oct 03 '24	Proposed Sale	22.56	972	21,928		Oct 03 04:17 PM
Lee Kevin	Officer	Oct 03 '24	Proposed Sale	22.56	3,212	72,462		Oct 03 04:15 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Jul 03 '24	Sale	19.64	246	4,831	22,645	Jul 08 06:57 PM
Skynner Michael	CHIEF TECHNOLOGY OFFICER	Jul 03 '24	Sale	19.64	967	18,992	93,917	Jul 08 06:55 PM
Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	Jul 03 '24	Sale	19.64	148	2,907	23,075	Jul 08 06:55 PM
Crockett Nigel	CHIEF BUSINESS OFFICER	Jul 03 '24	Sale	19.64	967	18,992	46,794	Jul 08 06:55 PM
Keen Nicholas	CHIEF SCIENTIFIC OFFICER	Jul 03 '24	Sale	19.64	779	15,300	62,024	Jul 08 06:55 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Jul 03 '24	Sale	19.64	3,194	62,730	384,076	Jul 08 06:55 PM
Milnes Alistair	CHIEF OPERATING OFFICER	Jul 03 '24	Sale	19.64	967	18,992	71,274	Jul 08 06:55 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Apr 11 '24	Sale	22.49	257	5,780	22,891	Apr 12 04:30 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Apr 03 '24	Sale	23.81	3,158	75,192	387,270	Apr 05 04:30 PM
Skynner Michael	CHIEF TECHNOLOGY OFFICER	Apr 03 '24	Sale	23.81	955	22,739	94,884	Apr 05 04:30 PM
Milnes Alistair	CHIEF OPERATING OFFICER	Apr 03 '24	Sale	23.81	955	22,739	72,241	Apr 05 04:30 PM
Crockett Nigel	CHIEF BUSINESS OFFICER	Apr 03 '24	Sale	23.81	955	22,739	47,761	Apr 05 04:30 PM
Keen Nicholas	CHIEF SCIENTIFIC OFFICER	Apr 03 '24	Sale	23.81	790	18,810	62,803	Apr 05 04:30 PM
Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	Apr 03 '24	Sale	23.81	152	3,619	23,223	Apr 05 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Bicycle Therapeutics Plc ADR

Upgrade your FINVIZ experience